menu
    • menu
    [{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure to Present Clinical Data at AACR 2020 Virtual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AST-008","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Presents Promising Interim Results from Ongoing Phase 1b\/2 Trial of Cavrotolimod at Virtual KOL Event Today","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Collaboration","leadProduct":"SNA-based Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":1.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Exicure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Exicure Provides Interim Results from Ongoing Phase 1b\/2 Clinical Trial of Cavrotolimod (AST-008)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Cavrotolimod","moa":"TLR9","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Exicure \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Exicure \/ Not Applicable"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,045.0 million","upfrontCash":"$45.0 million","newsHeadline":"Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":1.05,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.05,"dosageForm":"","sponsorNew":"Exicure \/ AbbVie","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Termination","leadProduct":"SNA-based Therapeutic","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":1.02,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":1.02,"dosageForm":"","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Exicure","sponsor":"Bluejay","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Licensing Agreement","leadProduct":"Cavrotolimod","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Exicure","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Exicure \/ Bluejay","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ Bluejay"}]

    Find Clinical Drug Pipeline Developments & Deals by Exicure

    Menu

    Exicure

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Bluejay

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for ...

                            Details : Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents including AST-008 (cavrotolimod), an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology...

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 05, 2024

                            Lead Product(s) : Cavrotolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Bluejay

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNA-based Therapeutic

                            Therapeutic Area : Dermatology

                            Study Phase : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $1,045.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements

                            Details : SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid thera...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $45.0 million

                            December 14, 2022

                            Lead Product(s) : SNA-based Therapeutic

                            Therapeutic Area : Dermatology

                            Highest Development Status : Preclinical

                            Sponsor : AbbVie Inc

                            Deal Size : $1,045.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNA-based Therapeutic

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,020.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Exicure Announces Termination of AbbVie and Ipsen Collaboration Agreements

                            Details : SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid thera...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : $20.0 million

                            December 14, 2022

                            Lead Product(s) : SNA-based Therapeutic

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,020.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008)

                            Details : Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. Cavrotolimod is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 05, 2021

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNA-based Therapeutics

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,020.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

                            Details : Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : $20.0 million

                            August 02, 2021

                            Lead Product(s) : SNA-based Therapeutics

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,020.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod

                            Details : Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. The U.S. FDA has granted Orphan Drug Designation for cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma ...

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 03, 2021

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administrat...

                            Details : The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous sq...

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 11, 2021

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35...

                            Details : Updated data from the Phase 1b stage demonstrated that the combination of cavrotolimod and pembrolizumab continued to be well tolerated, with a confirmed overall response rate (ORR) of 21% (4/19 patients) according to RECIST v1.1 criteria.

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 09, 2020

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Annivers...

                            Details : Cavrotolimod, the company’s SNA-enabled TLR9 agonist, is being developed for the treatment of solid tumors, in combination with anti-programmed cell death 1 (PD-1) therapy.

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 19, 2020

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed

                            Exicure

                            Ireland arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event ...

                            Details : The cavrotolimod pharmacodynamic profile corroborated the efficacy data, as increased serum cytokines/chemokines, activated immune cells, and tumor infiltration by immune cells were observed.

                            Brand Name : AST-008

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 16, 2020

                            Lead Product(s) : Cavrotolimod,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth